about
P184
Michelangelo and medicineConfirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritisBone mineral density improvement in spondyloarthropathy after treatment with etanerceptEfficacy of infliximab on MRI-determined bone oedema in psoriatic arthritisTumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluationSubclinical vasculitis in polymyalgia rheumaticaPTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locusInteraction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility.Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group.The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomesVariants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis.Transient rise in alkaline phosphatase activity in adults.Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris.Advances in the understanding of entheseal inflammation.Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis.Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis.Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS.Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the ClinicianComprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort.Early oligoarthritis.Ankylosing spondylitis: new treatment modalities.Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group.The evidence for whole-spine MRI in the assessment of axial spondyloarthropathy.Magnetic resonance imaging in spondyloarthritis.Optical coherence tomography: a new tool to assess nail disease in psoriasis?A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group.Emerging drugs for axial spondyloarthritis including ankylosing spondylitis.European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.The Use of Magnetic Resonance Imaging in Axial Spondyloarthritis: Time to Bridge the Gap Between Radiologists and Rheumatologists.Ankylosing spondylitis - the changing role of imaging.Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years.Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project.Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study.Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis.Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis.
P50
Q24537222-BE45DB56-49F8-47EA-83A8-0C40384BE95CQ24625936-9C162B8E-A142-4637-B542-5E9BFCB1C2EFQ24674266-69129C1D-7D52-436B-870C-87B07BDD548BQ24674877-57961839-9D4C-4FB3-BB64-383F0A952671Q28077713-D4982076-9B14-454F-AEA9-C37D0AAD3640Q28361777-DBDF2FA4-8B8D-4EC2-8B91-0C80DF081EE3Q28606478-5FD902EE-03BF-452A-8597-0AC860378FFBQ29417082-8D76A7CE-3BB9-4CF8-8C0D-F9D2E5CD1025Q30239856-2FD916FC-5A36-48B0-A5ED-21B737E179E7Q30251968-FAB83E17-E08F-4858-93AB-0BD72EA47170Q33916770-AE9F23C4-B328-469D-8684-F98A70D6959DQ34409780-99BF2B2A-A9EF-40AB-8310-4784CADE4BF5Q34527397-3C081D6F-6347-4DC8-B677-94005D217FF4Q34905406-9FCAEA6D-0A27-4D37-959D-8B19DE33C696Q34994482-9A7C41E5-ED71-4E58-8C4A-EE8D6C658AFBQ35637210-B151771E-1943-4A4A-BA8D-E709EC9647D6Q35750515-74767BB9-1C48-4A15-99E1-AFDD16BA0F7DQ35880376-26F2C531-6373-4611-941C-DCC286E00781Q36059338-CF5C7636-92EF-4557-9559-B55BBCF42E63Q36094040-45D0C61F-6EBB-480F-93AE-A1E3D1AA3C65Q36312904-34A922A1-72DE-4BFB-8B17-D217F7D695A7Q36507981-6AE073BF-E3D8-4688-AE69-4C4ED4D52017Q37488924-B944DEB2-2436-481C-8596-CA06865AB392Q37671982-11A11AEB-88BD-405B-95CD-9CF1DF69F096Q37729771-2A12E4E6-2C2D-44EE-AE32-E7B77BC74F22Q37906131-B96E3722-981D-47F2-ABCD-746E2C967E8AQ37908827-4E22369B-DA53-4F4A-A3E3-1B52EE97EB5AQ37939700-3B55872A-39C6-4B55-9431-53A22A7B6902Q38010148-D7D1CB52-2616-4318-A98F-A0F5ABC54C37Q38068578-C907D25F-F1FB-430C-B322-9DDE6E6B0ACBQ38661777-47D229C6-F10D-41A5-ACB9-CEF72156E4C9Q38862653-76385EF1-16BD-4A35-86A9-95D88D70AC78Q39598494-A42A1155-622B-4E89-AA3F-B59CFE1A70EDQ40031246-7F79D3B4-BFB7-4B8F-AB0B-F4A8C8C9F254Q40103638-5565505D-4C7B-4302-9D33-CAA373C1D338Q40318692-47DC59F1-CA04-4433-A6C2-BBB970CD2468Q40405924-F9A717F4-7735-4E4F-AB71-2EB0740376CEQ40550214-A09DEA00-E8FE-4C6F-83FF-4C41B59A3903Q40916807-2714300F-3583-49FD-9707-4FC910EF153CQ40948411-1CED6CD7-E4A8-449C-BBD1-A2BF00AABAF8
P50
description
hulumtuese
@sq
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Helena Marzo-Ortega
@ast
Helena Marzo-Ortega
@br
Helena Marzo-Ortega
@ca
Helena Marzo-Ortega
@cs
Helena Marzo-Ortega
@cy
Helena Marzo-Ortega
@da
Helena Marzo-Ortega
@de
Helena Marzo-Ortega
@de-at
Helena Marzo-Ortega
@de-ch
Helena Marzo-Ortega
@en
type
label
Helena Marzo-Ortega
@ast
Helena Marzo-Ortega
@br
Helena Marzo-Ortega
@ca
Helena Marzo-Ortega
@cs
Helena Marzo-Ortega
@cy
Helena Marzo-Ortega
@da
Helena Marzo-Ortega
@de
Helena Marzo-Ortega
@de-at
Helena Marzo-Ortega
@de-ch
Helena Marzo-Ortega
@en
prefLabel
Helena Marzo-Ortega
@ast
Helena Marzo-Ortega
@br
Helena Marzo-Ortega
@ca
Helena Marzo-Ortega
@cs
Helena Marzo-Ortega
@cy
Helena Marzo-Ortega
@da
Helena Marzo-Ortega
@de
Helena Marzo-Ortega
@de-at
Helena Marzo-Ortega
@de-ch
Helena Marzo-Ortega
@en
P106
P1153
6701624000
P1416
P185
P2031
1999-01-01T00:00:00Z
P2038
Helena_Marzo-Ortega
P21
P213
0000 0001 2432 8578
P31
P496
0000-0002-9683-3407
P6178
01036451264.52